Real-World Treatment and Outcomes in Resectable Early-Stage Non-Small Cell Cancer: THASSOS-INTL Australia Cohort.

Area of Science:

• Oncology
• Clinical Research

Background:

• Limited real-world data on treatment strategies and survival for Australian early-stage non-small cell lung cancer (NSCLC) patients.
• THASSOS-INL (NCT04808050) aimed to address this gap.

Purpose of the Study:

• Evaluate treatment patterns and survival outcomes in Australian patients with early-stage NSCLC.
• Analyze clinico-demographic factors influencing overall survival (OS).

Main Methods:

• Retrospective, non-interventional, multicenter study of the Australian cohort of THASSOS-INTL.
• Included patients (N=199) diagnosed with resectable stage IA-IIIB NSCLC between January 2013 and December 2017.
• Primary outcomes: treatment patterns and 3-year survival rates; Secondary outcomes: factors associated with OS.

Main Results:

• Most patients (97.0%) underwent surgery; neoadjuvant and adjuvant therapies were administered to 9.5% and 39.2%, respectively.
• Median overall survival (OS) was 6.0 years, with a 3-year survival probability of 70.5%.
• Factors significantly worsening OS included older age, advanced NSCLC stage, disease progression, and EGFR mutations.

Conclusions:

• Treatment approaches varied significantly prior to the availability of immuno-targeted therapies.
• Less than half of patients received adjuvant therapy (AT), and only a quarter of those received adjuvant chemotherapy (ST).
• Highlights the need for integrated molecular diagnostics, improved access to novel therapies, and multidisciplinary care to enhance NSCLC patient survival.